Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy

Immunogenic cell death

“…High Hydrostatic Pressure (Adkins et al, 2014, Microwave Thermal Ablation (Yu et al, 2014), Specific forms of Radiation therapy , Gameiro et al, 2014, Obeid et al, 2007, Schildkopf et al, 2011 and UVC irradiation …”

Thermal Ablation of Lung Tumors: Focus on Microwave Ablation

“…The heat also has an immunomodulatory effect by releasing intact antigens that can trigger an antitumor immune response [97,98]. Therefore, the size of the ablation zone can be enhanced by the concomitant local application of cytotoxic drugs [95,99].…”

Trial Watch—Oncolytic viruses and cancer therapy

“…Among this abundant literature, we found of especial interest the works of (1) Arulanandam and colleagues (Ottawa Hospital Research Institute, Ottawa, Canada), who discovered that a transcriptional modulator operating downstream of vascular endothelial growth factor receptors (VEGFRs) 208,209 suppresses Type I interferon (IFN) responses, 210 hence sensitizing the tumor vasculature to infection by oncolytic viruses, 211 and found that microtubule-destabilizing agents commonly employed in the clinic (e.g., paclitaxel) 212,213 synergize with oncolytic virotherapy by disrupting the translation of Type I IFN-coding mRNAs and by exacerbating the demise of cancer cells provoked by the cytopathic effect; 214 (2) Nishio and collaborators (Baylor College of Medicine, Houston, TX, US), who reported that an oncolytic adenovirus genetically engineered to express interleukin-15 (IL-15) and chemokine (C-C motif) ligand 5 (CCL5, also known as RANTES) improved the therapeutic potential of adoptively transferred T cells expressing a chimeric antigen receptor (CAR) 215,216 [218][219][220][221][222] a means to boost the replication (and hence the efficacy) of an oncolytic HSV-1 strain; 223 (4) Parrish and co-authors (St James's University Hospital, Leeds, UK), who discovered that an oncolytic reovirus enhances the capacity of the FDA-approved CD20-targeting monoclonal antibody rituximab 224,225 to stimulate antibody-dependent cellular cytotoxicity; 226 , who discovered that autonomous parvoviruses are endowed with a rather advantageous feature for the development of novel oncolytic virotherapies, namely, they neither trigger nor inhibit Type I IFN responses in normal and malignant cells; 236 (11) Zloza and coauthors (Rush University Medical Center, Chicago, IL, US), who suggested that the downregulation of leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 1 (LILRB1, also known as ILT2) in peripheral blood mononuclear cells may constitute a reliable biomarker of therapeutic responses to oncolytic virotherapy in cancer patients; 237 (12) Liikanen and colleagues (University of Helsinki, Helsinki, Finland), who propose that the circulating levels of the damage-associated molecular pattern high mobility group box 1 (HMGB1) [238][239][240][241] at baseline may constitute a robust prognostic factor as well as a predictive indicator of disease control up...…”